Kazia VP granted 150,000 stock options

Kazia Therapeutics reported that VP, Finance and Controller Jeffrey Bonacorda received a grant of employee stock options over 150,000 ADSs.

Rhea-AI Filing Summary

Kazia Therapeutics reported that VP, Finance and Controller Jeffrey Bonacorda received a grant of employee stock options over 150,000 ADSs. These options have an exercise price of $6.78 per ADS, set by reference to the Nasdaq closing price on January 8, 2026.

One-third of the options vest on January 8, 2027, with the remaining two-thirds vesting in equal annual tranches on each anniversary of that date. The options were granted for no cash consideration, are held directly, and will expire on January 8, 2029, if not exercised.

Insights

Equity compensation analyst

Routine option grant to finance executive, compensation-related and non-market.

The filing shows 150,000 stock options granted to VP, Finance and Controller Jeffrey Bonacorda at an exercise price of $6.78 per ADS. This is a board and Remuneration Committee–approved compensation award, not an open-market purchase or sale.

The options vest over three years starting January 8, 2027 and expire on January 8, 2029. Since this is a standard equity incentive grant with no associated sale, it is generally viewed as a routine compensation event rather than a directional signal about the company’s shares.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider Bonacorda Jeffrey

Role VP, Finance and Controller

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	150,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 150,000 contracts (Direct)

Footnotes (1)

1. F1. Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

Key Figures

Options granted: 150,000 options Exercise price: $6.78 per ADS Vesting start date: January 8, 2027 +4 more

7 metrics

Options granted 150,000 options Employee Stock Option grant over ADSs to VP, Finance and Controller

Exercise price $6.78 per ADS Set by reference to Nasdaq closing price on January 8, 2026

Vesting start date January 8, 2027 One-third of options vest on this Commencement Date

Remaining vesting period Two annual tranches Remaining two-thirds vest on anniversaries of January 8, 2027

Expiration date January 8, 2029 Options expire if not exercised by this date

Total derivative holdings after grant 150,000 options Total shares following transaction for this option award

Grant consideration $0.00 Options were granted for no cash consideration

Key Terms

ADSs, Remuneration Committee, exercise price, vesting, +2 more

6 terms

ADSs financial

"Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee"

Remuneration Committee financial

"award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026"

A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.

exercise price financial

"at an exercise price of $6.78 per ADS, which was set by reference to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"One-third of the options vest on January 8, 2027 and the remaining two-thirds vest in equal yearly tranches"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Commencement Date financial

"One-third of the options vest on January 8, 2027 (the "Commencement Date")"

options were granted for no consideration financial

"The options were granted for no consideration and expire on January 8, 2029"

FAQ

What did Kazia Therapeutics (KZIA) disclose about Jeffrey Bonacorda in this Form 4?

Kazia Therapeutics disclosed that VP, Finance and Controller Jeffrey Bonacorda received a grant of 150,000 employee stock options over ADSs. The award is a board and Remuneration Committee–approved equity compensation grant, not an open-market transaction involving cash purchases or sales of shares.

How many stock options did Jeffrey Bonacorda receive from Kazia Therapeutics (KZIA)?

Jeffrey Bonacorda received 150,000 employee stock options over Kazia Therapeutics ADSs. Following this grant, his derivative holdings reported in this filing total 150,000 options, reflecting the full amount of this new award as part of his equity-based compensation package.

What is the exercise price of Jeffrey Bonacorda’s options at Kazia Therapeutics (KZIA)?

The employee stock options granted to Jeffrey Bonacorda have an exercise price of $6.78 per ADS. This price was set by reference to the closing price of Kazia Therapeutics’ ADSs on Nasdaq on January 8, 2026, aligning the grant with the market level that day.

When do Jeffrey Bonacorda’s Kazia Therapeutics (KZIA) options vest?

One-third of the options vest on January 8, 2027, known as the Commencement Date. The remaining two-thirds vest in equal yearly tranches on each anniversary of that date, creating a three-year vesting schedule designed to encourage ongoing retention and performance.

When do Jeffrey Bonacorda’s stock options at Kazia Therapeutics (KZIA) expire?

The employee stock options granted to Jeffrey Bonacorda expire on January 8, 2029, if they are not exercised before that date. After expiration, any unexercised options will be forfeited, meaning they can no longer be converted into ADSs.

Did Jeffrey Bonacorda pay cash for the Kazia Therapeutics (KZIA) option grant?

No, the filing states the options were granted for no consideration, meaning Jeffrey Bonacorda did not pay cash to receive them. Any future value would come only if Kazia Therapeutics’ ADS price exceeds the $6.78 exercise price and the options are exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 04:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonacorda Jeffrey

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS, LEVEL 24

300 BARANGAROO AVENUE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance and Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$6.78	01/08/2026		A		150,000(1)		(1)	(1)	ADSs	150,000	$0	150,000	D

Explanation of Responses:

1. Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

	/s/ Jeffrey Bonacorda	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)